webinar register page

Webinar banner
BRCCH Webinar: Future of COVID-19 Research
The Botnar Research Centre for Child Health (BRCCH) cordially invites you to join us for a forward-looking webinar on the Future of COVID-19 Research. The event will focus on the theme “What is the trajectory of the pandemic and the future of COVID-19 research?” Keynote speakers will share insights into significant research progress to date and the roadmap ahead for COVID-19 research related to immunology, epidemiology and bioengineering.

Schedule:
15:00- Welcome by BRCCH Director Prof Georg Holländer
15:10- Keynote lecture by Prof Teresa Lambe OBE (University of Oxford) "Development and testing of the Oxford/AstraZeneca vaccine"
15:30- Keynote lecture by Prof Benjamin Murrell (Karolinska Institutet) "Neutralizing SARS-CoV-2 variants"
15:50- Keynote lecture by Prof Sai Reddy (ETH Zurich and BRCCH) "Identifying prospective variants of SARS-CoV-2 by deep mutational learning "
16:10- Q&A Panel Discussion
16:40- Closing

(banner visual: background image courtesy of National Institute of Allergy and Infectious Diseases)

Oct 21, 2021 03:00 PM in Zurich

Webinar logo
* Required information
Loading

Speakers

Prof Teresa Lambe OBE
The Lambe Group for Emerging Pathogens, The Oxford Vaccine Group and the Jenner Institute Laboratories, Dept of Paediatrics @University of Oxford
Assoc Prof Lambe will share her research insights into the immune response to SARS-CoV-2 and its vaccine. Her research group is part of the Covid-19 vaccine trial in the UK and has co-designed the vaccine and led the development and testing of the immune response after vaccination. Prof Lambe’s research investigates the establishment of protective immune responses following vaccination and the formation of adaptive immune memory. She is particularly interested in delineating the immune response post vaccination and also post natural infection to help develop vaccines and define correlates of protection. At the University of Oxford, her group uses platform technologies to develop vaccines against emerging and re-emerging pathogens. The group is currently developing vaccines against a number of outbreak pathogens including Crimean-Congo haemorrhagic fever virus, Lassa virus, Nipah virus, Influenza, Ebolavirus and coronaviruses. (visual: John Cairns/University of Oxford)
Prof Benjamin Murrell
Department of Microbiology, Tumor and Cell Biology @Karolinska Institutet
Prof Murrell will speak about his work on the H2020 CoroNAb project, studying antibodies and isolating nanobodies against SARS-CoV-2. Prof Murrell's previous research interests surrounded the evolution of the HIV envelope protein, and antibodies against it. Recently, he has applied this expertise to SARS-CoV-2 and its variants. Together with colleagues, he has identified nanobodies from immunized alpacas that may be potential SARS-CoV-2 therapeutics, and has conducted preclinical immunization studies attempting to boost responses to SARS-CoV-2 variants. This work is part of the CoroNAb consortium research project, funded under Horizon2020 as part of the EU’s emergency funding call for COVID-19. (visual: Karolinska Institutet)
Prof Sai Reddy
Lab for Systems and Synthetic Immunology, Department of Biosystems Science and Engineering @ETH Zurich & Vice Director BRCCH
Prof Reddy shares his recent work on developing a simultaneous diagnostic and genomic surveillance method for SARS-CoV-2 based on targeted deep sequencing. He also will also present new data from his group related to identifying variants of SARS-CoV-2 using a novel method called deep mutational learning. Prof Reddy’s research is focused on the emerging field of systems and synthetic immunology, with an aim towards developing technologies relevant to immunotherapy and biotechnology. He has developed a number of methods in systems immunology to improve our understanding of adaptive immunity, with a particular focus on immune repertoire sequencing. Recently, he founded two spin-off companies, deepCDR Biologics and Engimmune Therapeutics, which are both based on technologies developed in his research group on engineering antibodies or T cells.